Chronic open-angle glaucoma: case study

2017 ◽  
Keyword(s):  
Open Angle Glaucoma ◽  
Open Angle ◽  
Chronic Open Angle Glaucoma

A Cross-Over Trial Comparing Once Daily Levobunolol with Once and twice Daily Timolol

1995 ◽  
Vol 5 (3) ◽  
pp. 172-176 ◽  
Author(s):  
S.K. Akafo ◽  
J.R. Thompson ◽  
A.R. Rosenthal
Keyword(s):  
Baseline Level ◽  
Open Angle Glaucoma ◽  
Open Angle ◽  
Double Blind ◽  
Carryover Effect ◽  
Once Daily ◽  
Hypertensive Patients ◽  
Significant Difference ◽  
Ocular Discomfort ◽  
Chronic Open Angle Glaucoma

The intraocular pressure (IOP) lowering efficacy of once-daily levobunolol 0.5% was compared with timolol 0.5% twice-daily and timolol 0.5% once-daily in 20 chronic open angle glaucoma and 5 ocular hypertensive patients. The design used was a randomised double blind cross-over trial with three periods each of 8 weeks separated by 2 weeks of no treatment. We found that following levobunolol a two week washout was not sufficient for the IOP to return to its original baseline level suggesting that levobunolol is a longer acting drug than timolol. Adjusting for this carryover effect, we found no significant difference in the IOP lowering effect among the three regimes (p=0.53). Reduced cost, less ocular discomfort and better compliance are the main potential advantages of the once daily treatments.

Sign in / Sign up

Export Citation Format

Share Document